Bloomberg News

Cosmo Surges as Forecast Exceeds Analyst Estimate: Zurich Mover

January 25, 2013

Cosmo Pharmaceuticals SpA (COPN), the Italian company whose bowel-disease drug won U.S. approval this month, rose the most in more than two years after forecasting sales that were almost double an analyst’s estimate.

Cosmo jumped as much as 16 percent in Zurich, the biggest intraday advance since September 2010. The stock was up 10 percent at 42 Swiss francs as of 11:57 a.m., giving the Lainate, Italy-based company a market value of 630 million Swiss francs ($681 million). The number of shares traded was more than 48,000, about five times the daily average for the past three months.

Santarus Inc. (SNTS:US), which bought U.S. marketing rights for Uceris in 2008, won approval for the drug as a treatment for ulcerative colitis this month. The clearance is a “watershed” that “will vastly increase our revenue potential,” Cosmo founder and Chief Executive Officer Mauro Ajani said in a statement today. The company expects sales of 67 million euros ($90 million) this year and 108 million euros in 2014, it said.

Peter Welford, an analyst at Jefferies International Ltd. in London, has estimated revenue of 53.5 million euros in 2013 and 57.2 million euros in 2014, according to data compiled by Bloomberg.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus